Abstract: A protective device for a needle tube of a syringe, the protective device including a base; and a cover connected to the base, wherein the base s configured to cooperate with a needle carrier by positive form locking wherein the needle carrier supports the needle tube, wherein the cover is configured elongated along a longitudinal axis and defines an interior space in which the needle tube is storable so that a person is protected against an unintentional contact with the needle tube, wherein the cover is pivotably supported at the base so that the cover is transferable relative to the base within a pivot plane from a starting position where the needle tube is stored in the interior before being used for injection in a first pivot direction into an operating position where the needle tube is available for injection.

Abstract: Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL

Abstract: A device for the needle tube of a syringe includes a housing which can pivot on a carrier element for the needle tube and which has an open housing side in the pivoting plane of the housing such that the needle tube can be swung into the housing in order to be held there after being used for injection. The arrangement of the rear free end of the needle tube in the carrier element enables controlled piercing of the all of a container that is replaceable in the carrier element.

Abstract: The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Abstract: The present invention relates to humanized monoclonal agonistic antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and are capable of inducing CD40 signaling independent of Fey mediated CD40 receptor crosslinking for use as immune stimulatory agents.

Abstract: Monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody.

Abstract: The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Abstract: The present disclosure relates to nesting sub-spaces for a machine tool by reading in evaluation criteria for an arrangement of nested sub-spaces, generating sequence data for an arrangement of nested sub-spaces, repeatedly performing a process until the result data exceeds a specified range. The process includes: generating evaluation data by evaluating the sequence data with an evaluation algorithm, generating result data based on a combinatorial logic of the evaluation data with the evaluation criteria, generating calculation data from the sequence data, the evaluation data, and the result data using the evaluation algorithm, generating further sequence data taking into account the calculation data with the evaluation algorithm, and repeating the process until the result data exceeds a specified range. The calculation data acts onto the generation of new sequence data to improve an arrangement of nested sub-spaces with respect to evaluation criteria.

Abstract: The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fc? mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.

Abstract: A safety cover for coupling with an injection device, the safety cover including a base; a cover including an outer housing and an inner housing; and a hinge, wherein the base includes a needle mount which is configured for directed receiving of an injection needle along a receiving axis of the needle mount, wherein the outer housing is coupled with the inner housing in a coaxial arrangement relative to a longitudinal axis of the cover and mounted at the inner housing, at least partially surrounding the inner housing, wherein the cover is connected by the hinge with the base, so that the cover is pivotable relative to the base about a pivot axis formed by the hinge and oriented perpendicular to the receiving axis so that that the cover is pivotable from an initial position in a first pivoting direction into a treatment position.

Abstract: The present invention relates to methods for treating medical conditions and/or disorders characterized by uncontrolled or abnormal expression of members of the IL1R3 signaling pathway such as IL-1?, IL-1ß, IL-33, IL-36, IL1RA and/or IL1R3, as well as variants thereof. More specifically, the present invention relates to anti-IL1R3 antibodies for use in the treatment of an IL1R3-mediated inflammatory condition and/or disorder in a subject. Such conditions and disorders include but are not limited to inflammatory diseases, immune disorders, fibrotic disorders, eosinophilic disorders, infection, pain, a central nervous system disorder, an ophthalmologic disorder, Hereditary Systemic Inflammatory Diseases, and Systemic and Local Inflammatory Diseases and cancer associated chronic inflammation.

Abstract: A protective device for the needle tube of a syringe, including a housing which can be pivoted on a support base which has an open housing side in the pivot plane, so that the needle tube can be pivoted into the housing after being used for injection and wherein on the housing side, a retaining device is provided for the needle tube which has been pivoted inwards. The invention proposes that in addition to the connection of a film hinge in order to form a pivot axis, the support base and the pivotable housing are additionally connected together via a predetermined breaking point and wherein after being used for injection, the housing can be pivoted back over the destroyed predetermined breaking point.

Abstract: The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fey mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.

Abstract: The present invention relates to methods for treating medical conditions and/or disorders characterized by uncontrolled or abnormal expression of members of the IL1R3 signaling pathway such as IL-1?, IL-I?, IL-33, IL-36, IL1RA and/or IL1R3, as well as variants thereof. More specifically, the present invention relates to anti-IL1R3 antibodies for use in the treatment of an IL1R3-mediated inflammatory condition and/or disorder in a subject. Such conditions and disorders include but are not limited to inflammatory diseases, immune disorders, fibrotic disorders, eosinophilic disorders, infection, pain, a central nervous system disorder, an ophthalmologic disorder, Hereditary Systemic Inflammatory Diseases, and Systemic and Local Inflammatory Diseases and cancer associated chronic inflammation.

Abstract: A hot-rolling stand (10) for a hot-rolling mill comprises an adjusting device (12), which is intended for receiving a pair of work rolls (17) and for positioning work rolls (18, 19; 20, 21) of the pair of work rolls (17) in relation to one another to define a roll gap. In order to create a hot-rolling stand (10) that can be adapted as flexibly as possible, the adjusting device (12) is designed to interchangeably accommodate, in the pair of work rolls (17), different roll diameter ranges by means of mutually complementary work rolls (18, 19; 20, 21).

Abstract: A roll stand having work rolls mounted therein. The roll stand has at least one upper mounting rail, which is mounted on the drive-side roll stand frame and oriented in a transverse direction to a rolling line running through the roll stand. In order to be able to keep the assembly space in the roll stand over the rolling line free during rolling—except for a roll change—and still change the roll efficiently, the upper mounting rail is configured to be moved into the rolling line and out of the rolling line, starting from the drive-side roll stand frame.

Abstract: A method for manufacturing control of machining of workpieces in a manufacturing hall that includes providing a plurality of image acquisition devices configured to acquire image sequences of allocated observation areas, identifying an object to be tracked in a first image of a first image sequence using at least one object feature, determining positions of the object feature in images of subsequent image sequences, determining a current position of the object by localizing the object feature in a temporally current image of one of the image sequences, and assigning the position of the object feature in the temporally current image to a current position in the observation area of the image sequence that includes the temporally current image, and integrating the determined current position of the object into the manufacturing control of the hall.

Abstract: The present invention is directed to HER2 antibodies directed against an epitope between amino acids 342-652 of human HER2 for use in the treatment of HER2 related disorders in combination with a second HER2 inhibitor. More specifically the invention relates to methods and uses of MAB270 or antibodies having the same CDRs as MAB270 in combination with trastuzumab or pertuzumab in HER2 positive cancer.